Who
Steven Kelly
Director
Company insider
Files Form 4 as: Director, Artelo Biosciences; President and CEO, Carisma Therapeutics; President and CEO, CytRx Oncology.
In numbers
- Trades disclosed
- 36
- Buys
- 0
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 3
- Companies where not an officer
- 1
- First trade
- 29 Jun 2006
- Last trade
- 17 Jul 2026
- Last filed
- 21 Jul 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 17 Jul 2026filed 21 Jul 2026 | ARTL Artelo Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —136 at $0.00 | filing |
| 17 Jul 2026filed 21 Jul 2026 | ARTL Artelo Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —136 at $0.00 | filing |
| 30 Jan 2026filed 2 Feb 2026 | ARTL Artelo Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —292 at $0.00 | filing |
| 30 Jan 2026filed 2 Feb 2026 | ARTL Artelo Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —292 at $0.00 | filing |
| 28 Jan 2025filed 30 Jan 2025 | Carisma Therapeuticsoption or derivative | SEC FORM 4 Code A | —500,000 at $0.00 | filing |
| 20 Dec 2024filed 23 Dec 2024 | ARTL Artelo Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,750 at $0.00 | filing |
| 17 Jun 2024filed 18 Jun 2024 | Carisma Therapeuticsoption or derivative | SEC FORM 4 Code A | —125,000 at $0.00 | filing |
| 28 Feb 2024filed 1 Mar 2024 | ARTL Artelo Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —1,484 | filing |
| 28 Feb 2024filed 1 Mar 2024 | ARTL Artelo Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —9,634 | filing |
| 28 Feb 2024filed 1 Mar 2024 | ARTL Artelo Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —667 | filing |
| 28 Feb 2024filed 1 Mar 2024 | ARTL Artelo Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —667 | filing |
| 28 Feb 2024filed 1 Mar 2024 | ARTL Artelo Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —667 | filing |
| 28 Feb 2024filed 1 Mar 2024 | ARTL Artelo Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —1,083 | filing |
| 28 Feb 2024filed 1 Mar 2024 | ARTL Artelo Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,484 | filing |
| 28 Feb 2024filed 1 Mar 2024 | ARTL Artelo Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —9,634 | filing |
| 28 Feb 2024filed 1 Mar 2024 | ARTL Artelo Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —667 | filing |
| 28 Feb 2024filed 1 Mar 2024 | ARTL Artelo Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —667 | filing |
| 28 Feb 2024filed 1 Mar 2024 | ARTL Artelo Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —667 | filing |
| 28 Feb 2024filed 1 Mar 2024 | ARTL Artelo Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,083 | filing |
| 31 Jan 2024filed 2 Feb 2024 | Carisma Therapeuticsoption or derivative | SEC FORM 4 Code A | —438,000 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
No trade we could place in a sector.
Related people
Nobody else traded the same names lately.